Provided by Tiger Trade Technology Pte. Ltd.

Agios Pharmaceuticals

31.80
-0.6800-2.09%
Post-market: 31.800.00000.00%19:30 EDT
Volume:569.93K
Turnover:18.22M
Market Cap:1.89B
PE:-4.54
High:32.82
Open:32.82
Low:31.65
Close:32.48
52wk High:46.00
52wk Low:22.24
Shares:59.47M
Float Shares:50.09M
Volume Ratio:0.47
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.0075
EPS(LYR):-7.1203
ROE:-34.34%
ROA:-22.24%
PB:1.84
PE(LYR):-4.47

Loading ...

U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology

Reuters
·
Jun 15

Agios posts EHA 2026 investor event presentation on rare hematology pipeline

Reuters
·
Jun 15

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

TIPRANKS
·
Jun 15

Agios says Phase 3 RISE UP trial shows mitapivat boosts hemoglobin response in sickle cell disease patients

Reuters
·
Jun 13

Agios Showcases Rise up Phase 3 Results at Eha 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

THOMSON REUTERS
·
Jun 13

Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

TIPRANKS
·
Jun 11

Analysts Are Neutral on Top Healthcare Stocks: Stevanato Group (STVN), Agios Pharma (AGIO)

TIPRANKS
·
Jun 11

Agios Pharmaceuticals, Oscotec Sign Global Licensing Agreement for Cevidoplenib

MT Newswires Live
·
Jun 01

Agios posts investor deck on cevidoplenib licensing deal in immune thrombocytopenia (ITP)

Reuters
·
Jun 01

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

TIPRANKS
·
Jun 01

Agios licenses exclusive global rights from Oscotec to SYK inhibitor cevidoplenib in deal with USD 25 million upfront payment

Reuters
·
Jun 01

Agios Pharmaceuticals - Oscotec to Receive $25 Mln Upfront Plus Milestone Payments and Tiered Royalties

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Oscotec Eligible for up to $140 Mln in Development and Regulatory Milestones

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Oscotec Retains Option for Exclusive Rights to Cevidoplenib in South Korea

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals - Expects 2026 Operating Expense Guidance to Be Flat Compared to 2025

THOMSON REUTERS
·
Jun 01

Agios Enters Exclusive Global License Agreement With Oscotec to Develop and Commercialize Next-Generation Syk Inhibitor Cevidoplenib

THOMSON REUTERS
·
Jun 01

Agios Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
May 30

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)

TIPRANKS
·
May 30